Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Metabolon is a technology company, develops analytical methods and software for biomarker discovery using metabolomics. It offers a biochemical profiling platform that analyzes and identifies biochemicals in the research of pharmaceutical, biotech, agriculture, cosmetic, and consumer products. Metabolon provides a unique, real-time fingerprint of biological system to reveal novel discoveries and realize the promise of precision medicine. The company can deliver an instantaneous snapshot of the entire physiology of a living being at a discreet point in time, as well as identify changes in that system brought about the impact of the disease, medical intervention, diet, or the environment. This deep and comprehensive view of the metabolome provides biological insights that cannot be revealed through any other research methodology, enabling life sciences researchers and drug developers to discover answers to some of biology’s most difficult questions. Metabolon was founded in 2000 and headquartered in Durham, North Carolina.

Founded in 2008, they are a privately-held biotech company with two primary areas of business: Pre-clinical contract research (CRO) services and proprietary early target and drug discovery programs. Their focus is the metabolic space (obesity, diabetes, NASH and diabetic complications), where we specialize in in vivo pharmacology, peptide chemistry, molecular pharmacology, histology, 3D imaging, stereology, NGS (next generation sequencing), bioinformatics and ex vivo assays. Gubra is an abbreviation for GUt and BRAin, the original key focus areas of our research and expertise. They work with some of the most interesting and loyal partners and customers from across the world within big pharma, biotech and academia. Through a constant focus on high quality, scientific excellence, speed and solid teamwork, we have established ourselves as a highly professional and competent partner in the market.

Medtronic MiniMed, Inc. manufactures insulin pumps and glucose monitoring systems. Its products include minimed 530g system, smartguard, enlite sensor, minimed revel and infusion sets. The company was founded by Alfred E. Mann in 1979 and is headquartered in Northridge, CA.

Sensys Medical develops a non-invasive blood glucose monitor that used near-infrared diffuse reflectance spectroscopy.

Ziylo's mission is to help people with diabetes to live more normal and longer lives. Using its back ground in supramolecular chemistry the company has developed a third ‘biomimetic’ class of glucose binding molecule (GBM). These molecules are at the core of medical devices such as Continuous Glucose Monitors (CGM) and therapeutics such as Glucose Responsive Insulins (GRI). The platform is based on over 20 years of cutting-edge research pioneered by Professor Anthony Davis’ group at the University of Bristol. Inspired by nature's carbohydrate-binding molecules (lectins), Professor Davis has become a leader in the field of ‘Synthetic Lectins’ – biomimetic molecules that bind carbohydrates like glucose in blood. This award-winning chemistry has been published in Science and Nature Chemistry and has laid the foundation for the discovery the Biomimetic GBM platform.

FUJIFILM Corp. engages in the provision of imaging and information solutions. Its offers photography equipment, supplies and services, optical devices, healthcare, high-performance materials, graphic systems, recording media, and industrial products. The company was founded on October 2, 2006 and is headquartered in Tokyo, Japan.

Hangzhou Sciwind Biosciences Co., Ltd. (doing business as Sciwind) is a Chinese company located in Hangzhou. The firm engages in research and development of biological drugs. It was founded in 2017 by Hai Pan, who has been the CEO since that date.\nThe company says this about itself: Sciwind Biosciences is a clinical stage biopharmaceutical company focusing on discovering and developing innovative therapies to treat metabolic disease. Its product pipeline consists of potentially first-in-class and best-in-class drug candidates, including the long-acting GLP-1 peptide analog ecnoglutide (Phase 3), oral GLP-1 peptide analog XW004 (Phase 1), and oral small molecule GLP-1 receptor agonist XW014 (Phase 1). Sciwind has developed multiple proprietary technologies, including oral peptide and inhaled protein therapeutic delivery platforms and identified a series of drug candidates based on these core platform technologies.

F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Daegu-Gyeongbuk Medical Innovation Foundation is a cutting-edge drug and medical device production company.

Shanghai Gurney Biotechnology Co., Ltd., established on 2009-12-07, The scope of business includes technical consultation in the field of biological expertise,Technical Services,technology development,technology transfer,Business Consulting(In addition to brokerage),Chemical product sales(Removal of hazardous chemicals,Monitor Chemicals,firecrackers,civilian explosives,precursor chemicals),Engaged in the import and export of goods and technology.[Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to seek to create new targeted small molecule drug candidates for cancer. In expanding its drug development efforts in the field of cancer through its proprietary targeted cancer programs, Curis is building upon its previous experiences in targeting signaling pathways for the development of next generation targeted cancer therapies. For more information, visit Curis' website at www.curis.com.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Abbott Diabetes Care, Inc. manufactures glucose monitoring equipments. It designs, develops and manufactures glucose monitoring systems and test strips for use in both home and hospital settings. The company was founded on August 29, 2005 and is headquartered in Abbott Park, IL.

Merck Sharp & Dohme Corp. engages in the research, development, and distribution of vaccines, prescription drugs, and animal health products. The company is headquartered in Whitehouse Station, NJ.